SRx Health Solutions (SRXH) 2024 Sidoti Virtual Micro-Cap Conference summary

Strategic vision and business overview

• Aims to become a global health and wellness company serving both people and pets, anchored by premium pet nutrition and specialty pharmacy operations.

• Halo pet food targets high-income, highly engaged pet owners, with three product lines and strong growth in Asia-Pacific and the US digital channels.

• SRx Health operates over 30 specialty pharmacy locations in Canada, focusing on exclusive specialty drugs and patient support programs.

• SRx's patient support programs provide access to new therapies for chronic diseases, with recent contracts coming online end of year and into Q1 2025.

• Both businesses leverage asset-light models and strategic partnerships to drive efficiency and market reach.

Market trends and growth drivers

• Pet care industry benefits from humanization and premiumization trends, with consumers treating pets as family and seeking high-quality nutrition.

• Specialty pharmacy market is expanding due to rising chronic disease prevalence, with 40% of drug use now specialty and expected to grow.

• SRx's ecosystem includes infusion clinics, clinical trial sites, and proprietary technology, creating high barriers to entry and strong pharma relationships.

• Both pet and pharmacy businesses are experiencing double-digit growth, with significant opportunities in China and Asia-Pacific for pet food and in the US for specialty pharmacy.

• U.S. brands have a premium perception in China, where the pet food market remains fragmented and offers high growth potential.

Financial highlights and transaction details

• Combined company generated $95 million in net sales and positive EBITDA for the first six months of the year.

• Q3 saw 33% revenue growth and a 40% gross margin for the pet food business, with net income and EPS up year over year.

• Merger with SRx is an all-stock transaction, issuing $20 million in shares, resulting in 23 million fully diluted shares and a tightly held float.

• TTM sales for the combined entity are around $235 million, with strong organic growth and a large total addressable market.

• Both businesses expect to be at least cash flow neutral starting in 2025, with SRx generating free cash flow in Q1 2025.